February 18, 2020

Dicerna™ enters agreement with Roche to develop and commercialize DCR-HBVS for the treatment of chronic Hepatitis B Virus (HBV) infection

Dicerna is a previous MLSC Tax Incentive Awardee

Kudos to Dicerna Pharmaceuticals, Inc. on its research collaboration and licensing agreement with Roche to develop novel therapies for the treatment of chronic hepatitis B virus (HBV) infection.

Dicerna will receive $200 million up front plus up to $1.47 billion in potential milestone payments related to DCR-HBVS, the company’s investigational therapy in Phase 1 clinical development.

Dicerna is a 2019 Massachusetts Life Sciences Tax Incentive Program awardee. This past May, we announced $20 million in tax incentive awards to 27 life sciences companies to create more than 1,200 new jobs across the Commonwealth. These awards will support job growth in 19 different Massachusetts communities, the majority of which are located in or expanding outside of Boston and Cambridge.